1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma - Al-Batran, S-E; Haag, GM; Ettrich, TJ (Ann Oncol, 2020)
et al.